Albert Labs is developing KRN-101, a psilocybin-based therapy aimed at alleviating cancer-related anxiety, which affects over 15 million people globally. The company utilizes a patient-first approach and real-world evidence to expedite clinical trials and regulatory approval for its natural neurological treatments.
Funding
$605K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CCFounders
Product
Problem
Millions of cancer patients worldwide experience anxiety and distress, yet their psychological needs are often overlooked due to the complexities of cancer therapy. Existing mental health treatments can be ineffective and come with severe side effects, leaving a significant unmet need for these patients.
Solution
Albert Labs is a pharmaceutical company developing KRN-101, a psilocybin-based therapy, to address cancer-related distress. The company employs Real-World Evidence (RWE) studies to accelerate clinical trials and regulatory approval, leveraging existing clinic and research infrastructure. By focusing on patient-centric data and early clinician engagement, Albert Labs aims to deliver safe and effective neurological treatments to those most in need, offering a potential solution for the millions suffering from cancer-related anxiety and depression.
Target Audience
The primary target audience includes cancer patients experiencing anxiety and distress, as well as clinicians and hospital networks seeking innovative mental health solutions.
Features
- Utilizes KRN-101, a natural psilocybin medicine, in conjunction with psychotherapy
- Employs Real-World Evidence (RWE) to accelerate innovation and patient access
- Leverages existing clinic and research infrastructure for scalable trials
- Focuses on patient-centric data and early clinician engagement for effective treatment delivery
- Aims to provide a breakthrough for mental health care through psilocybin therapy